RxDoctor Payments Data

Sunjeet Sidhu, MD

Clinical Cardiac Electrophysiology · Baltimore, MDNPI 1285923862

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (43.5%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Medtronic at 45.6% of the total. Reporting peaked in 2019 at $8,935 and has fallen 56.2% since, to $3,910 in 2025.

$21,245in general payments, 2019–2025

Across 294 payments — averaging $72.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$10K
  • Abbott$7K
  • Biosense Webster, Inc.$3K
  • Philips North America LLC$848
  • Boston Scientific$626
  • Atricure, Inc.$371
  • plus $376 from 5 others
$21,315in research payments, 2019–2025

Across 31 payments — averaging $687.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$21K

What the payments were for

  • Consulting fees$8004%
  • Grants$5,83327%
  • Travel & lodging$4,62522%
  • Food & beverage$9,24344%
  • Charitable contribution$7444%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,245 in reported general payments places this provider in the 65th percentile of 63 clinical cardiac electrophysiology providers in Maryland.

See all clinical cardiac electrophysiology providers in Maryland

Medicare billing

Part B allowed, 2024
$510,871
Medicare patients
1,394
Services billed
4,917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$81,479
XareltoRivaroxaban17$24,002
Flecainide Acetate85$3,312
Metoprolol Succinate103$1,190
Amiodarone Hcl55$1,102
SotalolSotalol Hcl28$676
Metoprolol Tartrate18$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$29$24,00217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 63 clinical cardiac electrophysiology providers in Maryland.

Other clinical cardiac electrophysiology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →